Tempus AI annual revenue
2022
2023
2024
2025
Tempus AI Revenue Growth & History (TEM)
Tempus AI reported $1.27B in revenue for fiscal 2025, an increase of 83.41% from the previous fiscal year.
View full Tempus AI company overviewTempus AI annual revenue and growth
| Fiscal year | Period ended | Revenue | Change | Growth |
|---|---|---|---|---|
| 2025 | 2025-12-31 | $1.27B | $578.4M | +83.41% |
| 2024 | 2024-12-31 | $693.4M | $161.6M | +30.38% |
| 2023 | 2023-12-31 | $531.8M | $211.2M | +65.85% |
| 2022 | 2022-12-31 | $320.7M | — | — |
Tempus AI quarterly revenue
Q2.23
Q3.23
Q1.24
Q2.24
Q3.24
Q4.24
Q1.25
Q2.25
Q3.25
Q4.25
Q1.26
Q2.26
| Fiscal quarter | Period ended | Revenue | Change | YoY growth |
|---|---|---|---|---|
| Q2 2026 | 2026-06-30 | $382.5M | $67.9M | +21.56% |
| Q1 2026 | 2026-03-31 | $348.1M | $92.4M | +36.12% |
| Q4 2025 | 2025-12-31 | $367.2M | $166.5M | +82.98% |
| Q3 2025 | 2025-09-30 | $334.2M | $153.3M | +84.72% |
| Q2 2025 | 2025-06-30 | $314.6M | $148.7M | +89.57% |
| Q1 2025 | 2025-03-31 | $255.7M | $109.9M | +75.38% |
| Q4 2024 | 2024-12-31 | $200.7M | — | — |
| Q3 2024 | 2024-09-30 | $180.9M | $44.9M | +32.98% |
| Q2 2024 | 2024-06-30 | $166.0M | $33.6M | +25.34% |
| Q1 2024 | 2024-03-31 | $145.8M | — | — |
| Q3 2023 | 2023-09-30 | $136.1M | — | — |
| Q2 2023 | 2023-06-30 | $132.4M | — | — |
Tempus AI revenue growth trends
Tempus AI's latest reported quarter, Q2 2026, generated $382.5M in revenue, an increase of 21.56% year over year.
About the data
What revenue means
Revenue is the top-line amount a company reports from selling goods and services before expenses are deducted. Fiscal periods can differ from calendar years, so each table includes the exact period end date.
Financial data
Standardized company financials
TickerStat standardizes company financial facts for consistent comparison. Derived growth rates use the displayed values and are not guidance or forecasts.
Review Tempus AI source filings ↗Community posts
Tempus gains FDA clearance for mitral-regurgitation screening AI
Tempus AI ($TEM) has received FDA 510(k) clearance for ECG-MR, software that examines standard resting 12-lead electrocardiograms for signs associated with previously undiagnosed moderate or severe mitral regurgitation. It is the company’s ...
Tempus plans disease-focused dataset covering 100,000 whole genomes
Tempus AI ($TEM) launched an initiative to build a research platform linking 100,000 whole-genome sequences with long-term clinical information over several years. The company intends to focus on disease populations and treatment outcomes, ...
